ArticleClinical and experimental immunology2017
Human leucocyte antigen class I-redirected anti-tumour CD4
Article in Clinical and experimental immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- PD-1Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Trial
- Anti-PD-L2 immunotherapy is efficacious against melanoma in aged hosts through IL-17 and IFNγ signalling.Nature communications · 2025Article
- MHC-related protein 1-restricted recognition of cancer via a semi-invariant TCR-α chain.The Journal of clinical investigation · 2025Article
- NY-ESO-1 antigen: A promising frontier in cancer immunotherapy.Clinical and translational medicine · 2024Review
- Strategies and rules for tuning TCR-derived therapy.Expert reviews in molecular medicine · 2023Review
- Identification of cross-reactive CD8Genes & diseases · 2022Article
- Review
- Optogenetic Tuning of Ligand Binding to The Human T cell Receptor Using The opto-ligand-TCR System.Bio-protocol · 2020Article
- CD4 Inhibits Helper T Cell Activation at Lower Affinity Threshold for Full-Length T Cell Receptors Than Single Chain Signaling Constructs.Frontiers in immunology · 2020Article
- T Cell Reprogramming Against Cancer.Methods in molecular biology (Clifton, N.J.) · 2020Review
- High-affinity T cell receptors redirect cytokine-activated T cells (CAT) to kill cancer cells.Frontiers of medicine · 2019Article
- A rare population of tumor antigen-specific CD4Journal for immunotherapy of cancer · 2019Article
- Peptide Super-Agonist Enhances T-Cell Responses to Melanoma.Frontiers in immunology · 2019Article
- Is TCR/pMHC Affinity a Good Estimate of the T-cell Response? An Answer Based on Predictions From 12 Phenotypic Models.Frontiers in immunology · 2019Article
- Tristetraprolin Overexpression in Gastric Cancer Cells Suppresses PD-L1 Expression and Inhibits Tumor Progression by Enhancing Antitumor Immunity.Molecules and cells · 2018Article
- Peptide-MHC Class I Tetramers Can Fail To Detect Relevant Functional T Cell Clonotypes and Underestimate Antigen-Reactive T Cell Populations.Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- Article
- Optimized Peptide-MHC Multimer Protocols for Detection and Isolation of Autoimmune T-Cells.Frontiers in immunology · 2018Article
- NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.Frontiers in immunology · 2018Review
- Fine-Tuning of Optimal TCR Signaling in Tumor-Redirected CD8 T Cells by Distinct TCR Affinity-Mediated Mechanisms.Frontiers in immunology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.